Geode Capital Management LLC Grows Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Geode Capital Management LLC increased its stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 1.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 287,294 shares of the company’s stock after acquiring an additional 4,170 shares during the quarter. Geode Capital Management LLC’s holdings in ClearPoint Neuro were worth $3,222,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of CLPT. Point72 DIFC Ltd bought a new stake in shares of ClearPoint Neuro in the second quarter valued at about $32,000. Barclays PLC boosted its position in shares of ClearPoint Neuro by 24.3% in the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock worth $64,000 after purchasing an additional 1,109 shares in the last quarter. XTX Topco Ltd increased its holdings in shares of ClearPoint Neuro by 11.6% during the second quarter. XTX Topco Ltd now owns 13,010 shares of the company’s stock valued at $70,000 after acquiring an additional 1,353 shares in the last quarter. Verition Fund Management LLC acquired a new stake in shares of ClearPoint Neuro during the third quarter worth $123,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of ClearPoint Neuro in the third quarter worth about $156,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Price Performance

CLPT stock opened at $15.75 on Tuesday. The firm’s fifty day simple moving average is $13.57 and its 200-day simple moving average is $11.15. The company has a market capitalization of $434.46 million, a P/E ratio of -22.83 and a beta of 1.01. ClearPoint Neuro, Inc. has a 12 month low of $5.11 and a 12 month high of $17.47.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.